Loading…

Epigenome-wide association analyses of active injection drug use

Injection drug use (IDU) is prevalent in the US and is associated with substantial risk of blood-borne infections, morbidity, and mortality. However, the spectrum of its biologic effects on DNA methylation in blood is not well characterized. 401 participants (Mage = 47.9; 68% male; 90% African Ameri...

Full description

Saved in:
Bibliographic Details
Published in:Drug and alcohol dependence 2022-06, Vol.235, p.109431-109431, Article 109431
Main Authors: Shu, Chang, Jaffe, Andrew E., Sabunciyan, Sarven, Ji, Hongkai, Astemborski, Jacquie, Sun, Jing, Bakulski, Kelly M., Sosnowski, David W., Mehta, Shruti H., Kirk, Gregory D., Maher, Brion S.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Injection drug use (IDU) is prevalent in the US and is associated with substantial risk of blood-borne infections, morbidity, and mortality. However, the spectrum of its biologic effects on DNA methylation in blood is not well characterized. 401 participants (Mage = 47.9; 68% male; 90% African American) over several timepoints (1054 visits) were drawn from a longitudinal cohort of people who inject drugs. DNA methylation was measured among buffy coat samples from the 1054 visits. Compared to samples collected after ≥ 6 months of abstinence, separate EWAS were conducted for active injecting of any drug, quantitative injection frequency, injecting of heroin and injecting of cocaine. Linear mixed effect models were used and analyses were adjusted for repeated measurements and key technical, biological, and sociodemographic characteristics. We found epigenome-wide significant CpG sites associated with active injection (cg10636246, AIM2, p = 2.33 × 10−8) and injection intensity (cg13117953, p = 4.30 × 10−8). We found converging evidence that cg10636246 (AIM2), cg23110600 (PRKCH), cg03546163 (FKBP5), cg04590956 (GMCL1), and cg16317961 (MAPRE2) were among the top 0.1% significantly differentially methylated CpG sites shared across the five EWAS. Top ranked CpGs among the five EWAS were enriched (p 
ISSN:0376-8716
1879-0046
DOI:10.1016/j.drugalcdep.2022.109431